logo
Sign In
  1. Home
  2. Indications
  3. Chronic Lymphocytic Leukemia

Medications for Chronic Lymphocytic Leukemia

FiltersReset Filters
12 results

  • bendamustine hydrochloride

    (bendamustine hydrochloride)
    Baxter Healthcare Corporation
    Usage: Bendamustine Hydrochloride Injection is indicated for adult patients with chronic lymphocytic leukemia (CLL) and for those with indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

  • copiktra

    (duvelisib)
    Secura Bio, Inc.
    Usage: COPIKTRA is indicated for treating adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL) who have undergone at least two prior therapies.

  • cyclophosphamide

    (Cyclophosphamide)
    NorthStar RxLLC
    Usage: Cyclophosphamide for injection is indicated for treating various malignant diseases, including advanced lymphomas, multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, ovarian adenocarcinoma, retinoblastoma, and breast carcinoma. It is also used for pediatric patients with minimal change nephrotic syndrome who do not respond to corticosteroids.

  • cyclophosphamide

    (cyclophosphamide)
    Baxter Healthcare Corporation
    Usage: Cyclophosphamide for Injection is indicated for treating various malignancies in adults and pediatric patients, including malignant lymphomas, multiple myeloma, leukemias, and specific cancers like breast and ovarian carcinoma. It's also used for pediatric minimal change nephrotic syndrome when corticosteroid therapy fails.

  • cyclophosphamide

    (Cyclophosphamide)
    Amneal Pharmaceuticals LLC
    Usage: Cyclophosphamide for injection is indicated for treating various malignant diseases, including advanced lymphomas, multiple myeloma, several types of leukemia, mycosis fungoides, neuroblastoma, ovarian adenocarcinoma, retinoblastoma, and breast carcinoma. It is also used for pediatric minimal change nephrotic syndrome unresponsive to corticosteroids.

  • cyclophosphamide

    (cyclophosphamide)
    Bamboo US Bidco LCC
    Usage: Cyclophosphamide is indicated for treating various malignant diseases, including lymphomas, multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, ovarian adenocarcinoma, retinoblastoma, and breast carcinoma. It is also used for pediatric minimal change nephrotic syndrome unresponsive to corticosteroids. Safety in adults for this condition is not established.

  • gazyva

    (obinutuzumab)
    Genentech, Inc.
    Usage: GAZYVA is indicated for treating chronic lymphocytic leukemia (CLL) in combination with chlorambucil, and for follicular lymphoma (FL) in combination with bendamustine or chemotherapy, followed by monotherapy. It is used for relapsed/refractory FL post-rituximab and for untreated stage II bulky, III or IV FL.

  • imbruvica

    (Ibrutinib)
    Pharmacyclics LLC
    Usage: IMBRUVICA is indicated for adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), CLL/SLL with 17p deletion, Waldenström’s macroglobulinemia, and for treating chronic graft-versus-host disease in patients aged 1 year and older after failure of prior systemic therapy.

  • jaypirca

    (pirtobrutinib)
    Eli Lilly and Company
    Usage: JAYPIRCA® is indicated for adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two systemic therapies, including a BTK inhibitor. It is also indicated for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after two prior therapies, including a BTK and a BCL-2 inhibitor.

  • rituxan hycela

    (rituximab and hyaluronidase)
    Genentech, Inc.
    Usage: RITUXAN HYCELA is indicated for adult patients with relapsed/refractory and previously untreated follicular lymphoma, as maintenance therapy or after CVP chemotherapy. It treats diffuse large B-cell lymphoma in combination with CHOP, and chronic lymphocytic leukemia with fludarabine and cyclophosphamide. Not for non-malignant conditions.
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
For ProvidersRequest DemoJoin Research Panel
Prescribing toolsPrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutCareersContact Us
Get the latest insights in your inbox
  • Terms and Conditions
  • Privacy Policy
  • © 2026 PrescriberPoint. All Rights Reserved.